OBJECTIVES: The objectives of this study were to compare the serologic responses at week 48 to primary vaccination with 23-valent pneumococcal polysaccharide vaccine (PPV) vs. 7-valent pneumococcal conjugate vaccine (PCV); and to identify factors associated with serologic response in HIV-infected adult patients with access to combination antiretroviral therapy (cART). METHODS: One hundred and four CD4-matched pairs of HIV-infected patients who underwent primary pneumococcal vaccination with 23-valent PPV or 7-valent PCV were enrolled for determinations of anti-capsular antibody responses against four serotypes (6B, 14, 19F and 23F) at baseline, 24 weeks and 48 weeks following vaccination. Significant antibody responses were defined as 2-fold or greater increase of antibody levels at week 48 compared with baseline. The logistic regression model was used to determine the factors associated with serologic response to at least one and two serotypes. RESULTS: At week 48, patients who received PCV demonstrated a statistically significantly higher response rate to at least 2 serotypes than those who received PPV (37.5% vs. 20.2%, p = 0.006). In multivariate analysis, factors associated with significant antibody responses to at least one or two serotypes included receipt of PCV (adjusted odds ratio [AOR], 2.42 [95% CI, 1.23-4.78] and 3.58 [95% CI. 1.76-7.28], respectively), and undetectable plasma HIV RNA load (< 400 copies/ml) at vaccination (AOR, 1.47 [95% CI, 0.60-3.64] and 3.62 [95% CI, 1.11-11.81], respectively). CONCLUSIONS: Primary vaccination with 7-valent PCV achieved a significantly better serologic responses to one or two out of the four serotypes studied at week 48 than with 23-valent PPV in HIV-infected patients in the cART era. Suppression of HIV replication when primary vaccination was administered was associated with better serologic responses.
OBJECTIVES: The objectives of this study were to compare the serologic responses at week 48 to primary vaccination with 23-valent pneumococcalpolysaccharide vaccine (PPV) vs. 7-valent pneumococcal conjugate vaccine (PCV); and to identify factors associated with serologic response in HIV-infected adultpatients with access to combination antiretroviral therapy (cART). METHODS: One hundred and four CD4-matched pairs of HIV-infectedpatients who underwent primary pneumococcal vaccination with 23-valent PPV or 7-valent PCV were enrolled for determinations of anti-capsular antibody responses against four serotypes (6B, 14, 19F and 23F) at baseline, 24 weeks and 48 weeks following vaccination. Significant antibody responses were defined as 2-fold or greater increase of antibody levels at week 48 compared with baseline. The logistic regression model was used to determine the factors associated with serologic response to at least one and two serotypes. RESULTS: At week 48, patients who received PCV demonstrated a statistically significantly higher response rate to at least 2 serotypes than those who received PPV (37.5% vs. 20.2%, p = 0.006). In multivariate analysis, factors associated with significant antibody responses to at least one or two serotypes included receipt of PCV (adjusted odds ratio [AOR], 2.42 [95% CI, 1.23-4.78] and 3.58 [95% CI. 1.76-7.28], respectively), and undetectable plasma HIV RNA load (< 400 copies/ml) at vaccination (AOR, 1.47 [95% CI, 0.60-3.64] and 3.62 [95% CI, 1.11-11.81], respectively). CONCLUSIONS: Primary vaccination with 7-valent PCV achieved a significantly better serologic responses to one or two out of the four serotypes studied at week 48 than with 23-valent PPV in HIV-infectedpatients in the cART era. Suppression of HIV replication when primary vaccination was administered was associated with better serologic responses.
Authors: D R Feikin; C M Elie; M B Goetz; J L Lennox; G M Carlone; S Romero-Steiner; P F Holder; W A O'Brien; C G Whitney; J C Butler; R F Breiman Journal: Vaccine Date: 2001-11-12 Impact factor: 3.641
Authors: Sybil A Tasker; Mark R Wallace; Jeffrey B Rubins; William B Paxton; James O'Brien; Edward N Janoff Journal: Clin Infect Dis Date: 2002-02-07 Impact factor: 9.079
Authors: Mark T Dransfield; Sarah Harnden; Robert L Burton; Richard K Albert; William C Bailey; Richard Casaburi; John Connett; J Allen D Cooper; Gerard J Criner; Jeffrey L Curtis; Meilan K Han; Barry Make; Nathaniel Marchetti; Fernando J Martinez; Charlene McEvoy; Moon H Nahm; Dennis E Niewoehner; Janos Porszasz; John Reilly; Paul D Scanlon; Steven M Scharf; Frank C Sciurba; George R Washko; Prescott G Woodruff; Stephen C Lazarus Journal: Clin Infect Dis Date: 2012-05-31 Impact factor: 9.079
Authors: Cynthia G Whitney; Monica M Farley; James Hadler; Lee H Harrison; Nancy M Bennett; Ruth Lynfield; Arthur Reingold; Paul R Cieslak; Tamara Pilishvili; Delois Jackson; Richard R Facklam; James H Jorgensen; Anne Schuchat Journal: N Engl J Med Date: 2003-05-01 Impact factor: 91.245
Authors: Hannah M Garcia Garrido; Jenny L Schnyder; Michael W T Tanck; Albert Vollaard; René Spijker; Martin P Grobusch; Abraham Goorhuis Journal: EClinicalMedicine Date: 2020-11-23
Authors: Hannah M Garcia Garrido; Anne M R Mak; Ferdinand W N M Wit; Gino W M Wong; Mirjam J Knol; Albert Vollaard; Michael W T Tanck; Arie Van Der Ende; Martin P Grobusch; Abraham Goorhuis Journal: Clin Infect Dis Date: 2020-06-24 Impact factor: 9.079